Navigation Links
Cancer Advances Acquires the Intellectual Property for a Suite of Products that Enhance the Immune System in Treatment of Gastric, Pancreatic, and Colorectal Cancers
Date:2/2/2009

DURHAM, N.C., Feb. 2 /PRNewswire/ -- Cancer Advances, Inc. (Cancer Advances), a Cato BioVentures portfolio company, announced today that it has completed its acquisition of all the technology and intellectual property for a suite of products that enhance the immune system for application in three gastrointestinal cancers. Cancer Advances was created as a wholly owned subsidiary of Cato BioVentures to acquire products developed to inhibit the hormone, gastrin, for an undisclosed purchase price. This broad intellectual property portfolio includes composition and use-protection for a lead compound, Polyclonal Antibody Stimulator (PAS), that has been clinically studied in gastric, pancreatic, and colorectal cancers. Cato Research Ltd. (Cato Research) will be responsible for Cancer Advances' strategic drug development and regulatory activities.

"We are excited about continuing the development of PAS in pancreatic and gastric cancers," said Lynda Sutton, COO of Cato Research and President of Cancer Advances. "The flexible, broad-based strategic relationship between Cancer Advances, Cato BioVentures, and Cato Research position us well to execute our innovative drug development model where we are able to fully leverage our contract research and development resources while remaining capital efficient."

The purchase agreement includes multiple patents as well as clinical and safety data for the more than 1,100 patients who have been treated with PAS to date for gastric, pancreatic, and colorectal cancers. Cancer Advances will be seeking additional funding for the company as well as potential development partners.

About PAS

PAS is an active immunotherapeutic that induces antibodies against the hormone, gastrin 17 (G17), and its precursor, (gly)G17, of which there is extensive published evidence for a central role of both of these endogenous compounds in the development and progression of gastrointestinal
'/>"/>

SOURCE Cancer Advances, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Pioneering Cancer Center Introduces Advanced Varian RapidArc(TM) Treatments for Cancer Patients in Central Germany
2. Amgens Breakaway from Cancer Initiative Expands to Help Cancer Patients Access Broad Spectrum of Cancer Resources and Services
3. REXIN-G Shrinks Metastatic Tumors and Triples Survival Time in Chemotherapy-Resistant Pancreatic Cancer: Analysis of a U.S. Phase I/II Clinical Trial (Proceedings of ASCO GI Symposium 2009)
4. Introducing deCODEme Cardio(TM) and deCODEme Cancer(TM)
5. Rosetta Genomics and Collaborators Unveil Colon Cancer Screening Diagnostic; Identified Candidate MicroRNA Biomarkers in Serum
6. National Cancer Institute: Battling Cancer and a Recession
7. Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
8. Trinitas Comprehensive Cancer Center Now Offering Cancer Patients Faster, Ultra-Precise Radiation Using New RapidArc Technology
9. First Patient Dosed in Phase 2 Clinical Trial of NKTR-102 in Ovarian Cancer
10. Data Published in Nature Cell Biology Reveal Novel Function of Drug Target EpCAM in Cancer Cell Signalling
11. Genomic Health Announces Commencement of QUASAR Clinical Validation Study for Oncotype DX(R) Colon Cancer Assay
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... -- Research and Markets ( ... PharmaBiotech,s new report "Biomarkers - Technologies, Markets ... This report follows the broad definition of a ... measured and evaluated as an indicator of normal ... responses to a therapeutic intervention. Tests based on ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... ... development of botanical and plant-derived compounds. BCC Research reveals in its new ... 2020 because this market defines the category and generates the most market demand. ...
(Date:9/2/2015)... Sept. 2, 2015 Veracyte, Inc. (NASDAQ: ... , president and chief executive officer, will present at ... 16, 2015 at 10:30 a.m. ET in ... live audio webcast and subsequent replay may be accessed ... be available shortly after conclusion of the presentation and ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... ... critical demand to aid high-risk surgeries. From vital sign monitoring in ICU to ... Intel technology enables surgeon to make real-time clinical decisions with simultaneous access to ...
Breaking Biology Technology:Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 3Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 3Veracyte to Present at Morgan Stanley Global Healthcare Conference 2Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 2Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 3
...  Dyadic International, Inc. ("Dyadic") (OTC Pink: DYAI), a global ... sale of enzyme and protein products for the industrial ... will launch FibreZyme® G5000, a next generation, ... to improve paper quality and improve the economics of ...
... awareness about the disease and its overall occurrence and ... (MS) market. This is being exacerbated by the limited ... immediate need for innovative and enhanced therapeutic and diagnostic ... of treatment options. New analysis from Frost ...
... 2012   Kimberly-Clark Corporation (NYSE: KMB ... vice president of Global Nonwovens, has been named to ... in Corporate America." The Top 100 listing showcases ... and executives representing a diverse range of industries who ...
Cached Biology Technology:Dyadic International Launches FibreZyme® G5000 High Performance Powder Pulp and Paper Enzyme in Booth #1065 at Tissue World Americas Conference 2Dyadic International Launches FibreZyme® G5000 High Performance Powder Pulp and Paper Enzyme in Booth #1065 at Tissue World Americas Conference 3European Multiple Sclerosis Market in Dire Need of Increased Disease Awareness and Treatment Options, Cautions Frost & Sullivan 2European Multiple Sclerosis Market in Dire Need of Increased Disease Awareness and Treatment Options, Cautions Frost & Sullivan 3Kimberly-Clark's Bob Stargel Named One of Savoy Magazine's Top 100 Most Influential Blacks in Corporate America 2Kimberly-Clark's Bob Stargel Named One of Savoy Magazine's Top 100 Most Influential Blacks in Corporate America 3
(Date:8/6/2015)... and TELTOW, Germany , August ... Siggraph Conference, SensoMotoric Instruments (SMI) shows the ... , based on Epson,s Moverio BT-200 see-through ... platform. With this new solution, unprecedented quality and efficiency ... interaction with context-sensitive displays. For the first time, professionals ...
(Date:8/5/2015)... Calif. , Aug. 5, 2015 The ... continuous growth in applications, penetration into newer sectors, and ... year. The global biosensors space has seen the entry ... the market so far. (Photo - ... & Sullivan, Analysis of the Global Biosensors Market ...
(Date:7/31/2015)... Kina, 31. juli 2015 Den 10. internationale ... af BGI fra den 22. - 25. oktober i ... fejrer sin 10-års fødselsdag i år. Siden starten i ... årlige møder på ,omik,-feltet, og er en af de ... ICG-10 fokuserer på nylige gennembrud og fremskridt inden ...
Breaking Biology News(10 mins):SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2
... Center faculty have been elected to the Institute of Medicine ... Election to the Institute of Medicine (IOM) is one of ... and Columbia now has 49 members in this esteemed organization. ... Carolyn Westhoff were among the 65 new IOM members ...
... of the three most frequent malignancies in Western ... patients with early stage and local CRC approaches ... recurrence and the development of distant metastases that ... cause of CRC-related mortality. Although IL-8 ...
... publishers, has entered a publishing partnership with the Estuarine ... Appearing six times a year, the journal plays ... of estuarine and coastal ecosystems. The first issue ... partnership will be officially announced at the ERF 2007 ...
Cached Biology News:3 Columbia University Medical Center faculty elected to Institute of Medicine 2Interleukin-8, key marker for colorectal cancer treatment 2Estuarine Research Federation chooses Springer as publishing partner 2
Glutamate Receptor 5/1a...
Dual Color Mouse anti-Human Anti-Kappa FITC/CD19 PE Class: Antibody Product Group: Immunogluobulin...
... monoclonal [EP282Y] to Asparagine synthetase ... tested applications). ... to residues in the C-terminus ... Entrez GeneID: ...
Fluorescein isothiocyanate (FITC) mouse anti-human IFN-alpha2 50 ug...
Biology Products: